Table 2.
Different types of biologic disease-modifying antirheumatic drugs (bDMARDs) and other treatment modalities among patients with rheumatoid arthritis (RA).
| DAS28 < 3.2 (N = 8, 284) | DAS28 ≥3.2 (N = 2, 909) | Total (N = 11, 193) | p value | |
| Rituximab | 983.0 (11.9%) | 371.0 (12.8%) | 1, 354.0 (12.1%) | 0.207a |
| Adalimumab | 501.0 (6.0%) | 173.0 (5.9%) | 674.0 (6.0%) | 0.844a |
| Tocilizumab | 1, 835.0 (22.2%) | 358.0 (12.3%) | 2193.0 (19.6%) | <0.001a |
| Etanercept | 427.0 (5.2%) | 115.0 (4.0%) | 542.0 (4.8%) | 0.009a |
| Abatacept | 522.0 (6.3%) | 312.0 (10.7%) | 834.0 (7.5%) | <0.001a |
| Infliximab | 355.0 (4.3%) | 160.0 (5.5%) | 515.0 (4.6%) | 0.007a |
| All bDMARDs | 6, 602.0 (79.7%) | 2, 368.0 (81.4%) | 8, 970.0 (80.1%) | 0.047a |
| Patients on biologics | 4, 875.0 (58.8%) | 1, 603.0 (55.1%) | 6, 478.0 (57.9%) | <0.001a |
| Treatment type | 0.298a | |||
| Combination | 3, 283.0 (67.3%) | 1, 102.0 (68.7%) | 4, 385.0 (67.7%) | |
| Monotherapy | 1, 592.0 (32.7%) | 501.0 (31.3%) | 2, 093.0 (32.3%) |
aPearson's Chi-squared test.